Kazuhiko Nakagawa - Concepedia

Author

Kazuhiko Nakagawa

Also Known As

E Takeshita, H. Oe, Hirohito Tada, K Nakagawa, K. Nakagawa, K. Nakayama, KAZUHIKO NAKAGAWA, KAZUHIKO NAKAGAWA, M.D., Kazuhiko NAKAGAWA, Kazuhiko Nakagawa

1.4K

Publications

61.2K

Citations

102

H-Index

200

Concepts

All Affiliations

Kindai University National Cancer Center Hospital East Shizuoka Cancer Center National Hospital Organization Kyushu Cancer Center Kindai University Hospital

About

Kazuhiko Nakagawa is an author at Kindai University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	68	267	22.9K
2	Health Sciences	26	60	2.1K
3	Public Health	3	3	217
4	Natural Sciences	2	2	69
5	Engineering	1	1	81

Kazuhiko Nakagawa

533

Publications

56.6K

Citations

H-Index

Page 1

	Year	Citations
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, The Lancet Oncology Open LabelMedicineCancer GrowthPathologyCancer Genomics	2009	4.1K
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, New England Journal of Medicine	2013	3.4K
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer Benjamin Solomon, Tony Mok, Dong‐Wan Kim, New England Journal of Medicine	2014	3.2K
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, Journal of Clinical Oncology	2003	2.9K
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study Aurélien Marabelle, Marwan Fakih, Juanita Lopez, The Lancet Oncology	2020	2.4K
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, Journal of Clinical Oncology	2011	1.6K
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, The Lancet Oncology OncologyPathologyBronchial NeoplasmDacomitinib Versus GefitinibFirst-line Treatment	2017	1.2K
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, JAMA Oncology	2017	978
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, The Lancet MedicineRandomised Phase 3PathologyAlectinib Versus CrizotinibBronchial Neoplasm	2017	895
Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer Bob T. Li, Egbert F. Smit, Yasushi Goto, New England Journal of Medicine	2021	886

Page 1